All the Latest Game Footage and Images from Codename Cure II Codename CURE II is an upcoming co-operative first person shooter set in the aftermath of a zombie apocalypse. Create an elite military ...

Arcturus has escalated its inhaled CF candidate ARCT-032 to 15 mg daily and reported dose-responsive, significant reductions in mucus/mucus plugs on high-resolution CT; it plans a larger Phase 2b ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

[State of Electronics] have released their latest video about ARCTURUS, the 14th video in their series The Computer History of Australia. ARCTURUS was a research computer system developed on a ...

An update from Arcturus Therapeutics ( (ARCT)) is now available. On December 11, 2025, Arcturus Therapeutics announced the amicable departure of its Chief Financial Officer, Andy Sassine, effective ...

Payne indicated that the company intends to "evaluate daily dosing of ARCT-032 over a 12-week duration in up to 20 CF participants," with this study planned to begin in the first half of 2026. He ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...

After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants exhibited encouraging reduction of mucus plug number and mucus volume 12-week study enrolling up to 20 CF ...